Deep Genomics appoints James Dowling as Chief Medical Officer

June 24, 2019

Toronto, Ontario – June 24, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that James Dowling, M.D., Ph.D., is joining the team as Chief Medical Officer, effective today.

“Deep Genomics has identified therapeutic opportunities addressing hundreds of thousands of patients with rare genetic disorders,” said Brendan Frey, Founder and Chief Executive Officer. “Our first programs will enter the clinic next year. We require a clinical leader that understands and advocates for the needs of patients, is a world-class expert on rare disease biology, and can work closely with our team in developing AI systems to accelerate clinical development and increase success rates. Jim is ideal for this role and we are thrilled to welcome him to the team.”

James Dowling

“My interest in figuring out how to address the unmet therapeutic needs of patients with rare disorders is aligned with the mission of Deep Genomics,” said Dr. Dowling. “The tremendous growth in data and artificial intelligence will play a key role in the future of drug development, and I am delighted to join this interdisciplinary team and be part of that transformation. Together, we will create a more predictable and transparent drug development process, which will be hugely beneficial to patients with rare disorders.”


Dr. Dowling has been a lead investigator for both industry and academic sponsored clinical trials, and he co-discovered two clinical stage therapies for congenital myopathies. His medical practice and research focusses on neuromuscular medicine and child neurology, and he has made seminal contributions to the understanding of several rare disorders. Since 2013, Dr. Dowling has been with the Division of Neurology and the Program for Genetics and Genome Biology at the Toronto Hospital for Sick Children, where he will continue to hold a partial appointment.

Dr. Dowling received his M.D. from the University of Chicago Pritzker School of Medicine in 2001, his Ph.D. in molecular genetics and cell biology from the University of Chicago in 1998, and his M.S. and B.S. from Yale University. He completed his residency in child neurology at Children’s Hospital of Philadelphia, and held a neuromuscular and neurogenetics fellowship at the University of Michigan.

Says Frey, “Jim’s commitment to making all aspects of drug development faster, better, and more transparent is a perfect fit to our mission, and to our culture. We look forward to working with him.”

About Deep Genomics. Deep Genomics is creating a universe of individualized genetic medicines. It is building an AI Workbench that its team uses to accelerate all aspects of drug discovery and development, including target discovery, lead optimization and clinical trial design. The workbench combines artificial intelligence, machine learning, advanced robotics systems, the latest biomedical data, specialized software systems and high volume data acquisition. Deep Genomics is located in the heart of Toronto, next to the University of Toronto, four research hospitals, three medical research institutes, and the AI research labs of Google, Uber and the Vector Institute for Artificial Intelligence. Web: www.deepgenomics.com. Press: Megan Murphy megan@deepgenomics.com

Press release Jim Dowling as CMO

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'} p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'; min-height: 14.0px}